Login
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp

arbutusbio.com

What Do They Do?

Licenses lipid nanoparticle delivery technology to drug developers and develops drug candidates for people with chronic hepatitis B.

How Do They Make Money?

Collaborators and licensees pay for intellectual-property rights and research and development work through upfront payments, research funding, milestones and royalties.

revenue
SegmentShareRevenue
Collaborations and licenses
89%
FY2022: 80%
Non-cash royalty revenue
Licensed

11%
FY2022: 20%

Who Are Their Customers?

Third parties license its lipid nanoparticle technology for different applications; collaboration agreements also cover research and development services.

Do Revenues Turn Into Profits?

No. It lost $33.5M in FY2025.

Operating income, FY2025
−271% of revenue
▲ +50% (Loss) vs FY2024 (−$76.3M, −1237%)
Net income, FY2025
−238% of revenue
▲ +52% (Loss) vs FY2024 (−$69.9M, −1133%)
Free cash flow, FY2025
−281% of revenue
▲ +39% (Loss) vs FY2024 (−$65M, −1054%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −43%
vs $529K in Q3 FY2025
Net income
▲ Turned profitable
vs −$7.7M in Q3 FY2025
Collaborations and licenses share of revenue vs 52.9% in Q3 FY2025

Growing. Revenue grew 28% in 4 years, from $11M in FY2021 to $14.1M in FY2025, about 6% a year.

Narrower development scope The older report described hepatitis B programs alongside coronavirus drug research and oncology applications; the latest centers on hepatitis B candidates and lipid nanoparticle technology licensing.

Revenue over time
Collaborations and licenses Non-cash royalty revenue
$50M$25M$0

Who Do They Compete With?

Competes with GSK, Gilead Sciences, Assembly Biosciences, Aligos Therapeutics, AusperBio Therapeutics, Brii Biosciences, Mirum Pharmaceuticals, and Precision Biosciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support